We hypothesized that de novo donor-specific antibody (DSA) causes complement-dependent endothelial cell injury in kidney transplants, as assessed by expression of endothelial cell-associated transcripts (ENDATs), that may be attenuated through complement inhibition. In total, 15 participants (five control, 10 treatment) with DSA and deteriorating renal function were enrolled. The treatment group received 6 mo of eculizumab followed by 6 mo of observation, whereas controls were observed. The primary end point was percentage change in estimated GFR (eGFR) trajectory over the treatment period. The treatment group had an improved eGFR trajectory versus control, based on our predetermined two-sided 0.10 significance level (p = 0.09). Within-subject analysis of treated participants at 6-mo intervals did not show significant change (p = 0.60). Modeling C1q status showed that C1q-positive patients had significantly higher mean eGFR than patients with negative C1q (p = 0.04). Biopsies revealed elevated renal ENDATs in most participants, but ENDATs were not reduced with complement inhibition. Our data suggest that eculizumab treatment may stabilize kidney function in patients with chronic persistent DSA based on our pilot a priori significance threshold. ENDAT expression predicative of acute humoral injury is not reduced with complement inhibition in this chronic setting. Further studies will be necessary to determine which patients may benefit from eculizumab.
Introduction
Kidney transplantation is the preferred treatment for endstage renal disease because it is associated with improved survival and reduced costs compared with dialysis (1, 2) . Although short-term survival rates have improved with modern immunosuppression, little progress has been made in prolonging the longevity of kidney allografts. The ongoing demand for kidney transplantation now represents a public health crisis that is exacerbated by graft failure and the need for retransplantation (3, 4) .
The humoral theory of transplant rejection hypothesizes that the principal cause of late graft failure is pathological alloantibody (5) . The development of de novo donorspecific antibody (DSA) occurs in %30% of transplant recipients (6) and has emerged as the major previously underrecognized cause of allograft failure (7, 8) . The Genome Canada Study analyzed the major causes of late graft failure and showed that the histological diagnosis of antibody-mediated rejection is associated with the greatest conditional probability of late graft loss (9) . Understanding the mechanisms that underlie how and when alloantibodies cause injury in the chronic setting is necessary to develop potential therapeutic options for transplant patients who have DSAs and demonstrate slowly deteriorating graft function (10) .
Alloantibodies are known to cause tissue injury through both complement-mediated and complement-independent mechanisms (11) . Substantial evidence shows that DSAs that fix the complement component C1q are associated with greater transplant glomerulopathy and result in worse graft survival (8) , suggesting a putative role of complement-mediated injury. It is important, however, to recognize that the same study showed that non-C1q-fixing DSAs were also associated with worse graft survival compared with DSA-negative patients, signifying a potential role for noncomplement mechanisms causing direct allograft injury (8) .
In the setting of chronic persistent DSA, several factors and mechanisms may result in activation of the immune response against renal allografts. Antibody mean florescence intensity (MFI) (12) , IgG subclass (13), HLA class specificity (14) , epitope specificity (15) and the coexistence of other DSAs (16) are likely to have significant immunological implications for both the magnitude and the mechanisms of the humoral response. In addition, it is becoming increasingly evident that a cyclical injury and immune regulatory component exists in the setting of chronic persistent DSA, indicating that periods of activation and injury are likely interspersed among periods of quiescence. Consequently, alloantibody-induced immune activity may not be ascertainable by current clinical assessments that depend on for-cause renal biopsies only after renal dysfunction is appreciated (17, 18) .
Kidney transplant patients who develop DSAs have no firmly established treatment; however, they are clearly at higher risk of graft loss (6, 8, 10) . We hypothesized that the primary mechanism of chronic antibody injury is mediated through the activation of the complement cascade and that prolonged treatment with the terminal complement inhibitor eculizumab would stabilize graft function in patients who had developed de novo DSA and exhibited signs of slowly deteriorating renal function. As a corollary, we hypothesized that clinically effective complement inhibition would dampen the inflammatory response in protocol renal biopsies, detected by reduced expression of endothelial cell-associated transcripts (ENDATs) specific for allograft injury in the acute setting (18) . In this paper, we presented the results of a pilot, parallel-group, randomized controlled trial that was conducted to test these hypotheses.
Methods

Trial design, randomization, and blinding
This pilot intervention trial was designed using parallel groups with a 1:2 allocation ratio of observation versus investigational treatment using complete randomization. The 1:2 allocation ratio was designed to increase the sensitivity to detect adverse events in the investigational arm due to limited safety data with prolonged complement inhibition in the immunosuppressed kidney transplant population and the concern about greater infection risk. There were no changes to the methods or eligibility criteria following initiation of the trial. This pilot study was unblinded.
Participants
Participants aged 18-65 years who were >6 mo from their first transplant were identified for eligibility by determining whether they had measured de novo DSA MFI >1100. The rationale of this MFI threshold was determined by our institutional observation that this MFI level was approximately associated with positive flow crossmatches. Additional eligibility criteria included a 20% reduction in estimated GFR (eGFR) during the 12 mo prior to enrollment, estimated by the Chronic Kidney Disease Epidemiology Collaboration. Nearly all eligible patients had a history of forcause biopsy, which was reviewed to ensure that there was no diffuse irreversible end-stage organ injury (stage IV fibrosis) or evidence of T cell-mediated rejection. Patients with cellular components of rejection on their baseline study biopsy were withdrawn and treated with conventional antirejection therapy. Enrollment was open to participants with either C4d-positive or -negative staining at their entry biopsy. In addition, immunosuppression was assessed to ensure stable calcineurin or mammalian target of rapamycin levels over the 3 mo prior to randomization. Specific exclusion criteria included history of cytomegalovirus, polyoma virus, herpesvirus or recurrent bacterial infections. The study was approved by the Yale University institutional review board, registered with ClinicalTrials.gov (identifier NCT01327573) and conducted under a U.S. Food and Drug Administration investigational new drug application (IND 109, 360).
Outcomes
The primary outcome in the study was the difference in percentage change of eGFR trajectory over time between the control and treatment arms during the treatment period. Secondary end points included 1-year graft survival, incidence of biopsy-proven acute rejection, incidence of treatment failure (death, graft loss, loss to follow-up or withdrawal from trial) and expression of ENDATs measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
Intervention
Following randomization, participants assigned to the treatment arm received a meningococcal vaccination with a 2-week run-in period prior to receiving the first dose of eculizumab. Participants in the treatment arm received eculizumab for 6 mo followed by observation for 6 mo, whereas control participants were simply observed over a 12-mo period, which allowed assessments of within-subject differences in eGFR trajectory between the two 6-mo time periods. Estimates of GFR were conducted at baseline and monthly thereafter throughout the study period. Participants randomized to treatment received induction doses of intravenous eculizumab dosed at 600 mg per week for 4 weeks followed by 900 mg every 2 weeks for a total of 26 weeks.
Sample size
A total of 20 participants were calculated into the randomization schema to either eculizumab (n = 14) or observation (n = 6). This estimate provided 80% power at the two-sided 0.10 significance level to detect differences in changes of eGFR of 1.26 standard deviations or 90% power at the two-sided 0.10 significance level to detect a difference in changes of eGFR of 1.44 standard deviations. Sample size restrictions dictated a lower significance threshold often used in pilot and earlier phase studies and was largely determined by cost constraints associated with prolonged use of eculizumab. Because of the unanticipated high level of screen failures (Figure 1 ), the pilot nature of the study, and resource constraints, enrollment was terminated following randomization of 16 patients over %3.5 years, resulting in less power that was assumed a priori.
Statistical analysis
The baseline characteristics of the patients were compared between treatment groups by using descriptive statistics. The chi-square test or Fisher exact test was used for categorical variables, and the Wilcoxon rank sum test was used for continuous variables. Linear mixed-effects modeling was performed to analyze the primary outcome variable by comparing the average slope of the regression line over the treatment period between treatment groups and to test for statistical significance. Each participant's response during the trial was modeled by regressing eGFR against time. The intercept and slope of the regression were allowed to vary randomly between participants through inclusion of random effects. The models included fixed effects for baseline eGFR, treatment and time-by-treatment interaction. Primary outcome percentage change in eGFR was calculated as least squares means at each time point minus baseline eGFR, divided by the baseline eGFR including 95% confidence intervals. DSA MFI, C4d and C1q status were subsequently entered into the model as exploratory covariates to determine relevance. To detect whether there was a change in slope before and after treatment within treatment groups, a piecewise linear mixed-effects model was used. The linear mixed-effects model provides unbiased estimates of treatment effects under the assumption that missing data are missing at random and are independent of outcome, given observed data. All analyses were conducted using SAS software version 9.4 in the SAS System for Windows (SAS Institute, Cary, NC).
ENDAT analysis
Total RNA was isolated from kidney biopsy specimens through homogenization in 0.5 mL QIAzol (Qiagen, Valencia, CA) according to the QIAzol handbook (steps 1-7 of the QIAzol protocol for lysis and homogenization). Samples were cleaned using the RNeasy MinElute spin protocol following the manufacturer's instructions (Qiagen), and the amount of RNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE).
TaqMan qRT-PCR was performed using validated primer/probe sets (Applied Biosystems, Foster City, CA) encoding the following genes: CAV1 Hs00971716_m1, CDH5 Hs00901463_m1, END1 Hs01115919_m1, PALMD Hs00927401-m1, PECAM1 Hs01065281_m1, SELE Hs009 5040_m1, VWF Hs01109453_m1 and HPRT 432621E. Briefly, reverse transcription was performed using with oligo-dT primers according to the Multiscribe RT system protocol (Applied Biosystems). All RT-PCR reactions were prepared with TaqMan 29 PCR Master Mix and predeveloped assay reagents from Applied Biosystems. Samples were analyzed on a BioRad CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). RNA samples processed without the RT enzyme were used as negative controls for all genes assayed. The expression level of each target was normalized to that of GAPDH.
Changes in the levels of messenger RNA were determined by measuring the cycle threshold (Ct), that is, the PCR cycle at which an increase in reporter fluorescence can first be detected above a baseline signal. Ct values for GAPDH complementary DNA (cDNA) were subtracted from Ct values for appropriate cDNA for each well to calculate DCt. The triplicate DCt values for each sample were averaged. The averaged DCt values calculated for normal kidney samples were subtracted from DCt values calculated for the patient biopsy samples to calculate DDCt, and the fold induction for each well was calculated using the 2 À(DDCt) formula. The fold induction value for triplicate wells was averaged, and data are presented as the mean plus or minus standard error of the mean of triplicate wells. A power calculation was performed based on the fold induction.
Results
Participants From July 6, 2011, to February 27, 2015, 16 patients were randomized to either treatment with eculizumab (n = 11) or observation (n = 5). We screened 420 patients for the presence of de novo DSA and determined that 88 patients had DSAs that met our MFI inclusion criteria ( Figure 1 ). Of these patients, 42 had eGFR that decreased at least 20% over the previous 12 mo. If patients had a recent biopsy within 2 mo that met inclusion and exclusion criteria, they were approached for participation in the study. If there was no biopsy within the prior 2 mo, they were asked to give consent for a research biopsy to determine eligibility. There were no significant differences in demographics between the groups (Table 1) . There was a predominance of HLA-DQ DSA in both groups but no differences in the number of C4d-positive patients at baseline (Table 1) .
One patient, randomized to the treatment group, was withdrawn from the study because of baseline biopsy findings of severe, recurrent, focal segmental glomerusclerosis and rapidly deteriorating renal function noted between the time of randomization and the baseline study visit and was referred for treatment of recurrent disease. With this exclusion, the study involved 10 patients in the eculizumab arm and five control patients.
Clinical end points
The primary outcome in the study was the difference in percentage change of eGFR trajectory over time between the control and treatment arms during 6-mo treatment versus 6 mo of control observation. The study was designed to assess between-and within-group differences in eGFR. Figure 2 shows a spaghetti plot of the independent observations with associated means. Of note, this figure shows the significant heterogeneity in baseline renal function in both groups, requiring longitudinal data analysis that provided assumptions of random intercept and variability between individual participant values.
Mixed-effects model analysis that incorporated the independent variables of baseline eGFR, group assignment, time and group-by-time interactions showed a nonsignificant difference at month 6 (p = 0.68) ( Table 2 ) but an improved trajectory of renal function in the treatment group based on our predesignated lower significance threshold of 0.10 (p = 0.09) (Table 2, Figure 3 ). Modeling using baseline DSA MFI as a covariate did not show a significant difference between the groups during the 6-mo treatment period (data not shown). At baseline, one of five control patients (20%) and five of 10 patients (50%) in the investigational arm were positive for C1q binding. Modeling incorporating baseline C1q binding showed that positive C1q was associated with a mean increase in eGFR (p = 0.04) (data not shown); however, treatment effect was not significant at the 0.10 significance level after adjusting for C1q status. We specifically looked at the five treatment patients who had positive C1q at baseline to assess whether they had a different treatment response compared with the five C1q-negative patients. Although a trend suggested improved eGFR stabilization in the C1q-positive group, this difference did not reach statistical significance (p = 0.16) (data not shown).
We performed an additional analysis using percentage change in 6-mo eGFR, calculated by 6-mo eGFR minus baseline eGFR divided by baseline eGFR; this measurement was an a priori end point that we had designated. The outcome using this measure showed that the mean percentage change in eGFR was 2.3 mL/min per 1.73 m 2 higher in the treatment group versus the control group; however, this difference did not reach statistical significance (p = 0.9). This calculation does not consider the known correlation between repeated eGFR measurements and is not as efficient statistically as our mixedeffects model analysis (19) .
We observed that half of the treatment patients appeared to have subjective differences in eGFR slope following cessation of eculizumab treatment (Figure 4) . To test the validity of this observation, we conducted piecewise linear mixed-effects modeling of within-subject differences for all treatment patients between the 6-mo treatment and 6-mo observation periods. This analysis did not demonstrate significant differences between these two intervals in treated patients (p = 0.60) ( Figure 5 ).
We performed renal biopsies on both arms at baseline and at 3, 6, and 12 mo. Although DSAs were not observed to change significantly at these time periods (data not shown), we noted significant variability in longitudinal C4d staining (Table 3) . Banff classification scoring was performed on all protocol kidney biopsies. Consistent with the large variability of baseline eGFR, the pathological scores were very heterogeneous and did not show significant changes in Banff scoring elements between or within groups (data shown in the supporting information). This p-value was for the overall slope difference between groups (i.e. the interaction between group and time).
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Figure 3: Mixed model analysis of eGFR slope comparing study arms during the first 6 mo. Analysis used eGFR, group, time, and group-by-time variables. Treated participants showed stabilization of renal function at the a priori 0.1 significance level (p = 0.09). eGFR, estimated GFR.
Mechanistic end points
All protocol biopsies were analyzed by qRT-PCR for ENDAT expression patterns that have been associated with antibody-mediated injury in the acute setting (18) . Figure 6 shows ENDATs normalized to GAPDH, with comparator lines determined by ENDAT expression from normal renal biopsies. The complete time course of renal biopsies was analyzed simultaneously to avoid intrarun variability. Results demonstrated that some markers, namely, SELE, PECAM-1, VWF and PALMD, were upregulated over levels in normal kidney; however, there was no statistical significance between biopsies from eculizumab-treated patients compared with trial controls (Figure 6 ). Other ENDATs, namely CAV1, HPRT, CHD5, and END1, showed no differences from normal human kidney in either treatment or control participants. Table 4 shows adverse events that occurred during this clinical trial. There were no significant differences in adverse events between the two arms of the study. There were no deaths or episodes of biopsy-proven acute rejection. One graft failed in the control arm, and two grafts failed in the treatment arm, one of which occurred in the observation period following cessation of eculizumab treatment. The prolonged 6-mo exposure to eculizumab in this immunosuppressed population did not result in greater occurrence of all-cause adverse events, particularly infectious complications.
Adverse events
Discussion
In this clinical trial, we tested whether terminal complement inhibition would attenuate antibody-mediated injury in kidney transplant patients with chronic persistent DSA. We also tested subsidiary hypotheses that antibodymediated chronic graft injury induced by complementmediated mechanisms would result in elevated expression of ENDATs in protocol renal biopsies and that the inhibition of terminal complement assembly would result in a reduction in ENDAT expression. This trial was designed and implemented with the understanding that Figure 5 : Piecewise linear mixed-effects modeling demonstrated no statistical difference between eGFR slopes comparing treatment (s1) and observation intervals of all treated participants (s2; p = 0.60). eGFR, estimated GFR; s1, slope 1; s2, slope 2. 
+, C4d positive; À, C4d negative; Ø, no biopsy. Figure 4 : Five of the 10 treatment group patients were noted to have subjectively decreasing eGFR slopes following cessation of treatment at 6 mo. eGFR, estimated GFR. Figure 6 : ENDAT analysis of kidney biopsies performed at baseline and at 3, 6, and 12 mo. ENDAT expression of SELE, PECAM1, VWF, and PALMD were noted to be higher than levels in normal kidneys for both groups; however, there was no reduction in ENDAT expression in eculizumab-treated patients. ENDAT, endothelial cell-associated transcript.
DSA-mediated injury could be detected independently of complement C4d deposition on graft peritubular cells (18) , which was and continues to be a marker of humoral rejection (20, 21) . Takemoto et al proposed that there were putative stages of humoral responses to allografts in which the development of DSA occurred prior to biopsy findings or graft dysfunction (22) . Later stages showed complement deposition followed by histological changes and then graft dysfunction (22) . It is now evident that DSA-mediated injury, particularly in the setting of chronic persistent DSA, is far more dynamic and involves cyclical injury and repair mechanisms that are currently undetectable using clinical parameters alone. This is supported by the fluctuating changes seen in longitudinal C4d deposition that have been reported and that are consistent with the longitudinal C4d data in this study (Table 4 ) (17).
The analysis of our primary end point showed that 6 mo of eculizumab treatment provided stabilization of renal function compared with the gradual decline in renal function noted in the control group ( Figure 3 ). This pilot study used a lower significance threshold of 0.10 to provide power in this study, which was limited based on the significant amount of resources and cost of treating this cohort with the investigational agent over a 6-mo period.
Additional post hoc exploratory analysis using models that included baseline DSA MFI, baseline C4d status or baseline C1q status failed to demonstrate significant treatment effects between the groups. Although our study was powered for 20 patients, due to resource concerns, it was terminated at 15 patients, leaving the study underpowered. We found that our ability to attain statistical significance (p < 0.10) for our primary end point despite this deficiency was an encouraging preliminary finding that may be used to test this hypothesis in larger, later phase studies.
Although participant enrollment was not dependent on HLA isotype or serotype, we noted that the vast majority of patients in both arms had DSAs to HLA-DQ (Table 1) . Emerging evidence suggests that anti-HLA-DQ antibodies are associated with late graft loss, and importantly, analysis of IgG subclasses of anti-HLA-DQ antibodies has shown that both complement-fixing and noncomplement-fixing isotypes are present (23) . Although C1q binding and/or subclass characteristics may be important in determining response to anticomplement treatment, determinants of isotype switching in the setting of chronic persistent DSA has not been ascertained and could result in changing mechanisms of injury at different time points. The critical gap that currently exists for these patients is making the determination of when DSAs are pathological and by what mechanism they are causing injury.
This study had several limitations. First, there was significant heterogeneity in the participant population in terms of baseline renal function, eGFR trajectory prior to enrollment, DSA MFI and date from transplant. Future studies would require a larger cohort from several centers with determination of complement-fixing activity at different time points throughout the study. Second, the optimal study design would have included a crossover structure in which control patients also received treatment following a fixed period of observation. Our study used this design only in the treatment arm. Third, the MFI inclusion criteria used in this study reduced the likelihood of detecting a treatment response, given the now-known association between the magnitude of MFI and poor clinical outcome; however, we noted that both arms had similar median MFI at enrollment that was well above our inclusion threshold ( We used ENDAT analysis, which has been shown to be predictive of antibody-mediated injury in the acute setting, and attempted to determine whether this technology platform could be used in the setting of chronic persistent DSA. The aim was to determine whether this analysis could further elaborate if and when DSAs were pathological in the chronic setting, providing an indicator for therapeutic intervention. The limited number of biopsy samples and the variation in patient sampling over time may have played a role in the lack of treatment effect that we observed. Biopsy samples taken over time can be problematic because of differences in gene expression from the biopsy site and a possible injury and repair mechanism that could potentially alter the expression of endothelial damage-related gene transcripts. In addition, it is also possible that there was substantial background inflammation in the kidneys that would mask a treatment effect. Our results suggest that ENDAT analysis used to determine humorally mediated injury in the acute setting cannot be used reliably to predict pathological alloantibody responses in the chronic setting.
Studies such as ours that investigate chronic antibody graft injury highlight unique challenges in the field of transplant research. First, regardless of the lack of Lumenix (Austin, TX) standardization, clinically relevant MFI thresholds in the chronic setting are unknown, although some outcome studies have shown that MFI thresholds as low as 700 may be clinically relevant (10) . Our study used a low threshold for inclusion; however, the observed median values in each investigational arm were substantially higher ( Table 1 ). The only substantive evidence that should guide decision making regarding antibody relevance is the association with clinical eGFR trajectory, which is the variable we included in our enrollment criteria. Second, chronic changes by definition take longer time periods to develop and are challenging to study. Recent studies have shown that patients with de novo DSA have very slow annual decline, and renal function and apparent histological changes take >1 year to become evident (14) . Investigating therapeutic agents that stabilize graft function in clinical conditions with such slow disease progression requires either a large treatment effect or large numbers of patients to detect statistical significance. Last, as observed in our study, this population is very heterogeneous, with large variances in baseline renal function, pathology and time from transplant. Baseline histology is particularly difficult to control because Banff scoring systems are not easily adjustable in statistical modeling, given the number of variables.
In summary, this pilot study provided preliminary data that DSA-mediated allograft injury may be partially attributed to complement-mediated mechanisms and may be attenuated by eculizumab treatment. This pilot study also provided preliminary safety information in the prolonged use of eculizumab in the immunosuppressed kidney transplant population; no increased occurrence of infections was observed. The underpowered nature of this pilot study and the significant participant heterogeneity increased variability and reduced the ability to detect treatment responses at established statistical significance levels (p < 0.05). Nevertheless, we were able to demonstrate a treatment effect at our a priori 0.10 significance threshold, which was established because of the pilot nature of this study. Larger studies designed to assess complement fixation throughout the investigational period are necessary to make a determination of which subgroup of patients may benefit from anticomplement therapies in the setting of chronic persistent DSA.
